FoundMyFitness · 2018-10-01 · Rhonda Patrick (host), Dale Bredesen

Dr. Dale Bredesen on Preventing and Reversing Alzheimer's Disease

47 claims checked against research: 1 contradicted 5 overstated 1 needing context 35 supported 5 unverified

Contradicted by research

The ApoE4 allele was the primordial human isoform present during roughly 96% of hominid evolution, whereas chimpanzees lack ApoE4.

"and that's actually the primordial one. It's the one that was present for about 96% of hominid evolution. If you look at a chimp, for example, it does not have ApoE4, but the hominids do." (said at 0:14:55)

The speaker combines two claims: that ApoE4 is the ancestral (primordial) hominid isoform present throughout most of human evolutionary history, and that chimpanzees lack ApoE4. While genetic analysis confirms that ApoE4 (with arginine residues at positions 112 and 158) is indeed the ancestral primate state from which ApoE3 and ApoE2 subsequently derived roughly 200,000 to 300,000 years ago, chimpanzees and other non-human primates actually possess the ApoE4-equivalent isoform (Arg112/Arg158). Chimpanzees do not lack ApoE4; rather, their APOE sequence is monomorphic and closely related to human epsilon-4.

contradicts: Apolipoprotein E variation at the sequence haplotype level: implications for the origin an… (American journal of human genetics 2000) · cited 434x in the literature
"Sequence analysis of the chimpanzee APOE gene showed that it was most closely related to human epsilon4-type haplotypes, differing from the human consensus sequence at 67 synonymous (54 substitutions and 13 indels) and 9 nonsynonymous fixed positions. The evolutionary history of allelic divergence within humans was inferred from the pattern of haplotype relationships. This analysis suggests that haplotypes defining the epsilon3 and epsilon2 alleles are derived from the ancestral epsilon4s and that the epsilon3 group of haplotypes have increased in frequency, relative to epsilon4s, in the past 200,000 years." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the anc… (Atherosclerosis 1995) · cited 132x in the literature
"The only differences between these isoforms result from cysteine-arginine interchanges at codons 112 and 158. There is considerable disagreement in the literature concerning the identity of the ancestral allele. In order to resolve this, 24 chimpanzees and individuals from a number of other primate species were analysed. All were similar to apo E4. This suggests that apo E4 is the ancestral allele and that apo E2 and apo E3 arose after the split of the human and chimpanzee lineages." (abstract, results, passage verified)
pubmed full study (doi)

Overstated

0:20:50 Dale Bredesenoverstatedmoderate

Elevated homocysteine levels correlate with more rapid cerebral gray matter and hippocampal volume loss, and normalizing homocysteine halts this volume decline.

"And of course, it's been published that you have a more rapid decline in your cerebral gray matter volume and hippocampal volume if you have a high homocysteine... but then if you improved the homocysteine and brought it back to normal... people actually stopped their decline and leveled off." (said at 0:20:50)

In older adults with mild cognitive impairment and elevated baseline homocysteine, randomized trial data (such as the VITACOG trial) show that high homocysteine is associated with faster whole-brain and gray matter atrophy (including within the medial temporal lobe), and that homocysteine-lowering therapy with B vitamins (folate, B6, and B12) significantly slows the rate of accelerated volume loss (by up to 53% for whole-brain atrophy in those with high baseline homocysteine). However, the claim overstates the effect by asserting that brain volume loss completely stopped or leveled off; the treatment slowed accelerated atrophy toward typical aging rates rather than halting volume decline entirely.

partial: Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild co… (PloS one 2010) · cited 814x in the literature
"The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P = 0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P = 0.001)." (abstract, results, passage verified)
pubmed full study (doi)
partial: Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. (Proceedings of the National Academy of Sciences of the United States of America 2013) · cited 526x in the literature
"In the placebo group, higher homocysteine levels at baseline are associated with faster GM atrophy, but this deleterious effect is largely prevented by B-vitamin treatment. We additionally show that the beneficial effect of B vitamins is confined to participants with high homocysteine (above the median, 11 µmol/L) and that, in these participants, a causal Bayesian network analysis indicates the following chain of events: B vitamins lower homocysteine, which directly leads to a decrease in GM atrophy, thereby slowing cognitive decline." (abstract, results, passage verified)
pubmed full study (doi)

0:09:48 Dale Bredesenoverstatedvery low

Patients categorized with type 3 (toxic or cortical) Alzheimer's disease characteristically present with low serum zinc, elevated copper-to-zinc ratios, and low serum triglycerides.

"many of the people with the type 3, the toxic subtype, have low serum zinc, high copper-to-zinc ratios, and low triglycerides." (said at 0:09:48)

In a 2015 paper introducing a proposed metabolic subtyping system for Alzheimer's disease, Dr. Dale Bredesen described 'type 3' (a cortical/toxic subtype) as being associated with 'striking zinc deficiency' (PMID: 26343025). However, this classification framework and its associated biomarker claims—including low serum zinc, elevated copper-to-zinc ratios, and low triglycerides—are derived from small case reports and observational hypothesis-generating work rather than validated clinical trials or established diagnostic guidelines.

partial: Metabolic profiling distinguishes three subtypes of Alzheimer's disease. (Aging 2015) · cited 81x in the literature
"The third type is a very distinctive clinical entity that affects relatively young individuals, extends beyond the typical Alzheimer's disease initial distribution to affect the cortex widely, is characterized by early non-amnestic features such as dyscalculia and aphasia, is often misdiagnosed or labeled atypical Alzheimer's disease, typically affects ApoE4-negative individuals, and is associated with striking zinc deficiency." (abstract, results, passage verified)
pubmed full study (doi)

0:31:00 Dale Bredesenoverstatedmoderate

Individuals who are APOE4-positive absorb dietary fat better than those who are APOE4-negative.

"If you are APOE4-positive, you're actually a better fat absorber, as you know, so you want to want to make that 14 to 16 hours." (said at 0:31:00)

The claim that APOE4 carriers absorb dietary fat or cholesterol more efficiently is based primarily on indirect surrogate markers (such as serum plant sterols/phytosterols), where APOE4 carriers often show elevated ratios. However, direct mass-balance and tracer studies measuring intestinal absorption efficiency have demonstrated no significant differences across APOE phenotypes. Elevated postprandial triglyceride-rich lipoproteins (chylomicron remnants) observed in APOE4 carriers are primarily driven by delayed clearance and hepatic processing rather than superior intestinal absorption of dietary fat.

supports: Apolipoprotein E phenotype regulates cholesterol absorption in healthy 13-month-old childr… (Pediatric research 2001) · cited 45x in the literature
"The 16 apoE4 children had 30% to 50% higher cholesterol-adjusted campesterol and sitosterol concentrations in serum than the 20 apoE 3/3 children (p = 0.002 and p = 0.02, respectively)." (abstract, results, passage verified)
pubmed full study (doi)
contradicts: Efficiency of intestinal cholesterol absorption in humans is not related to apoE phenotype… (Journal of lipid research 2003) · cited 37x in the literature
"Cholesterol absorption did not differ between the three groups of subjects and averaged 38 +/- 2% (mean +/- SEM) in normolipemic E2/2, 37 +/- 4% in type III hyperlipemic E2/2, and 41 +/- 3% in E4/4 subjects, respectively. Dietary intake of fat and cholesterol had no influence on cholesterol absorption efficiency." (abstract, results, passage verified)
pubmed full study (doi)
context: Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipopr… (The Journal of clinical investigation 1996) · cited 98x in the literature
"In both groups, TRL apo B48 increased at 3 h but returned to postabsorptive values at 6 h only in the apo E3/3 group; in the apo E4/3 group the concentration of apo B48 at 6 h was 80% higher than postabsorptive values... These observations suggest that clearance of intestinal and hepatogenous TRL remnants is impaired in young men with an apo E4/3 phenotype." (abstract, results, passage verified)
pubmed full study (doi)

0:33:34 Dale Bredesenoverstatedvery low

Alzheimer's and cognitive decline patients maintain better outcomes when blood beta-hydroxybutyrate levels are between 1.5 mM and 4.0 mM.

"We're finding that people who have higher ketone levels, 1.5 millimolar to 4 millimolar beta-hydroxybutyrate, tend to do better than those who are down lower, APOE4-positive and APOE4-positive or negative." (said at 0:33:34)

While systematic review and meta-analytic evidence indicates that inducing ketosis or supplementing with exogenous ketones can yield modest overall cognitive improvements (standardized mean difference of 0.29), there is no controlled clinical evidence establishing that a specific blood beta-hydroxybutyrate window of 1.5 mM to 4.0 mM produces superior clinical outcomes compared to lower levels in patients with cognitive decline or Alzheimer's disease regardless of APOE4 status. Targeted ketone levels within multimodal programs (such as the ReCODE / KetoFLEX 12/3 protocol) are based on preliminary observational series and uncontrolled pilot studies rather than isolated, dose-comparison trials.

context: The effect of exogenous ketone bodies on cognition across health and disease: a systematic… (Frontiers in nutrition 2026) · cited 2x in the literature
"EK supplementation was associated with a statistically significant improvement in cognitive performance compared with placebo (SMD = 0.29, 95% CI 0.16-0.41; p < 0.001). Sub-group analyses did not show statistically significant differences between the type of supplementation ( p = 0.083), study duration (acute vs. intermediate; p = 0.11), population type (healthy vs. Alzheimer's disease; p = 0.077), or the presence of acute cognitive stressors ( p = 0.89)." (abstract, results, passage verified)
pubmed full study (doi)
context: KetoFLEX 12/3 Diet and Cognitive Health: A Precision-Nutrition Perspective on Mechanisms, … (Nutrients 2026)
"Although much of the current evidence remains mechanistic, observational, or derived from multimodal intervention studies, the framework offers a biologically plausible precision-nutrition model that may inform future research and clinical investigation in cognitive decline." (abstract, conclusions, passage verified)
pubmed full study (doi)

0:53:00 Dale Bredesenoverstatedlow

Research by Stephen Genuis showed that cadmium concentration in human sweat can be over 1,000 times higher than in blood.

"you know, some nice work by Dr. Stephen Genuis from Canada, who showed that if you look at composition of sweat compared to the blood, there are certain toxins that are very high, cadmium being the big one, you know, over a thousand times increase in sweat." (said at 0:53:00)

Research by Dr. Stephen Genuis and colleagues (including the Blood, Urine, and Sweat study and a 2012 systematic review) found that heavy metals like cadmium are excreted through perspiration and can be more concentrated in sweat than in blood plasma or serum. In some participants, toxic elements were measurable in sweat even when non-detectable in serum. However, the claim that cadmium concentration in sweat is 'over 1,000 times' higher than in blood exaggerates the findings published in these studies. Furthermore, the body of evidence relies on small observational samples and descriptive reviews, providing low certainty overall.

partial: Blood, urine, and sweat (BUS) study: monitoring and elimination of bioaccumulated toxic el… (Archives of environmental contamination and toxicology 2011) · cited 131x in the literature
"Presumably stored in tissues, some toxic elements readily identified in the perspiration of some participants were not found in their serum." (abstract, results, passage verified)
pubmed full study (doi)
partial: Arsenic, cadmium, lead, and mercury in sweat: a systematic review. (Journal of environmental and public health 2012) · cited 108x in the literature
"Cadmium was more concentrated in sweat than in blood plasma." (abstract, results, passage verified)
pubmed full study (doi)

Needs context

0:14:22 Dale Bredesenneeds contexthigh

Apolipoprotein E was discovered by Robert Mahley.

"And of course, Professor Robert Mahley discovered this decades ago, and it has turned out to be the most important genetic risk factor for Alzheimer's disease." (said at 0:14:22)

The statement requires minor historical context regarding discovery, but is accurate regarding the role of APOE in Alzheimer's disease. Apolipoprotein E was first identified in human plasma lipoproteins in 1973 by Bernard and Virgie Shore as the 'arginine-rich apoprotein.' Robert W. Mahley and colleagues subsequently played a foundational role in isolating, characterizing, naming, and elucidating the structural and receptor-binding functions of apolipoprotein E across several decades. As stated, APOE (specifically the ε4 allele) has been firmly established as the most prominent genetic risk factor for late-onset Alzheimer's disease.

context: Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. (Journal of molecular medicine (Berlin, Germany) 2016) · cited 845x in the literature
"Apolipoprotein (apo) E was initially described as a lipid transport protein and major ligand for low density lipoprotein (LDL) receptors with a role in cholesterol metabolism and cardiovascular disease. It has since emerged as a major risk factor (causative gene) for Alzheimer's disease and other neurodegenerative disorders." (abstract, passage verified)
pubmed full study (doi)

Supported by research

0:01:30 Dale Bredesensupportedhigh

Alzheimer's disease is the most common cause of cognitive decline and dementia.

"Alzheimer's is the most common cause of cognitive decline, ultimately dementia." (said at 0:01:30)

Epidemiological evidence and systematic reviews consistently establish that Alzheimer's disease is the most frequent cause of progressive cognitive impairment and dementia worldwide, accounting for an estimated 60% to 80% of all dementia cases.

supports: Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, a… (AIMS neuroscience 2026)
"Alzheimer's disease (AD) is the most common cause of dementia, representing a major global public health challenge as populations age. It accounts for roughly 60%-80% of all dementia and is characterized by progressive cognitive decline, memory impairment, and eventual loss of independence in daily functioning." (abstract, passage verified)
pubmed full study (doi)

0:02:52 Dale Bredesensupportedmoderate

Research by Rudolph Tanzi and Robert Moyer at Harvard showed that amyloid-beta possesses antimicrobial properties.

"Professor Rudy Tanzi and Professor Robert Moyer at Harvard a few years ago showed that it is an antimicrobial." (said at 0:02:52)

Research led by Rudolph Tanzi and Robert Moir (phonetically rendered as 'Moyer') at Harvard Medical School and Massachusetts General Hospital demonstrated that amyloid-beta acts as an antimicrobial peptide (AMP). In a 2010 study (Soscia et al.), they demonstrated in vitro that amyloid-beta inhibits the growth of multiple clinically relevant pathogens with potency comparable to LL-37, a classic human antimicrobial peptide, and that antimicrobial activity in Alzheimer's brain homogenates correlated with amyloid-beta levels. In a 2016 follow-up (Kumar et al.), they further showed in vivo in transgenic mouse and Caenorhabditis elegans models that amyloid-beta expression protects against microbial infection via oligomerization and entrapment of pathogens.

supports: The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. (PloS one 2010) · cited 1041x in the literature
"Here, we provide data supporting an in vivo function for Abeta as an antimicrobial peptide (AMP). Experiments used established in vitro assays to compare antimicrobial activities of Abeta and LL-37, an archetypical human AMP. Findings reveal that Abeta exerts antimicrobial activity against eight common and clinically relevant microorganisms with a potency equivalent to, and in some cases greater than, LL-37." (abstract, results, passage verified)
pubmed full study (doi)
supports: Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheim… (Science translational medicine 2016) · cited 985x in the literature
"We present in vivo data showing that Aβ expression protects against fungal and bacterial infections in mouse, nematode, and cell culture models of AD. We show that Aβ oligomerization, a behavior traditionally viewed as intrinsically pathological, may be necessary for the antimicrobial activities of the peptide." (abstract, results, passage verified)
pubmed full study (doi)

0:03:05 Dale Bredesensupportedhigh

Research by Ashley Bush showed that amyloid-beta binds divalent metals including copper, zinc, and iron.

"as Professor Ashley Bush showed a number of years ago, it's actually quite a good binder of divalent metals like copper and zinc and things like that, iron." (said at 0:03:05)

The claim is supported by published biochemical literature co-authored by Ashley I. Bush demonstrating that amyloid-beta (Aβ) binds divalent metal ions, including copper, zinc, and iron. Bush and colleagues characterized specific metal-binding sites on Aβ, showing that Cu²⁺ and Zn²⁺ directly bind the peptide, inducing aggregation and oligomerization (PMID 10936205, PMID 11274207). Review literature authored by Bush further synthesizes these findings, noting that Aβ and its precursor protein (APP) interact with metal ions such as zinc, copper, and iron, and that high concentrations of these biometals accumulate in amyloid plaques in diseased brains (PMID 15709482, PMID 17119284).

supports: Characterization of copper interactions with alzheimer amyloid beta peptides: identificati… (Journal of neurochemistry 2000) · cited 639x in the literature
"We have previously reported that Cu(2+) and Zn(2+) bind amyloid beta (Abeta), explaining their enrichment in plaque pathology. Here we detail the stoichiometries and binding affinities of multiple cooperative Cu(2+)-binding sites on synthetic Abeta1-40 and Abeta1-42." (abstract, results, passage verified)
pubmed full study (doi)
supports: Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically order… (The Journal of biological chemistry 2001) · cited 654x in the literature
"Cu(2+) and Zn(2+) bind Abeta, inducing aggregation and giving rise to reactive oxygen species. These reactions may play a deleterious role in the disease state, because high concentrations of iron, copper, and zinc have been located in amyloid in diseased brains." (abstract, background, passage verified)
pubmed full study (doi)
supports: Amyloid-beta metal interaction and metal chelation. (Sub-cellular biochemistry 2005) · cited 67x in the literature
"Abeta and its precursor protein (APP) interact with metal ions such as zinc, copper and iron. Evidence shows that these metals play a role in the precipitation and cytotoxicity of Abeta." (abstract, background, passage verified)
pubmed full study (doi)

0:06:15 Dale Bredesensupportedmoderate

In insulin resistance, IRS-1 phosphorylation is altered such that serine/threonine phosphorylation increases relative to tyrosine phosphorylation, altering cellular insulin signaling.

"So you actually phosphorylate your IRS-1, as showed very nicely by Professor Ed Goetzl over at UCSF, so you've changed the ratio of the serine/threonine phosphorylation to the tyrosine phosphorylation, and you're literally changing your response to insulin." (said at 0:06:15)

Research led by Edward Goetzl and colleagues demonstrated that in conditions characterized by insulin resistance (including Alzheimer's disease and type 2 diabetes), neural-derived exosomes exhibit an elevated ratio of serine-phosphorylated IRS-1 (such as pSer312-IRS-1, associated with impaired insulin signaling) relative to tyrosine-phosphorylated IRS-1 (p-panTyr-IRS-1, representing normal active signaling). This shifted phosphorylation ratio directly impairs downstream insulin receptor pathway responsiveness.

supports: Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood e… (FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2015) · cited 352x in the literature
"Brain tissue studies suggested that insulin resistance is caused by low insulin receptor signaling attributable to its abnormal association with more phospho (P)-serine-type 1 insulin receptor substrate (IRS-1) and less P-tyrosine-IRS-1. [...] Mean exosomal levels of extracted P-serine 312-IRS-1 and P-pan-tyrosine-IRS-1 by ELISA and the ratio of P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 (insulin resistance factor, R) for AD and DM2 and P-serine 312-IRS-1 and R for FTD were significantly different from those for case control subjects." (abstract, results, passage verified)
pubmed full study (doi)
supports: Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzhei… (Human brain mapping 2017) · cited 131x in the literature
"Brain insulin resistance (IR), which depends on insulin-receptor-substrate-1 (IRS-1) phosphorylation, is characteristic of Alzheimer's disease (AD). Previously, we demonstrated higher pSer312-IRS-1 (ineffective insulin signaling) and lower p-panTyr-IRS-1 (effective insulin signaling) in neural origin-enriched plasma exosomes of AD patients" (abstract, background, passage verified)
pubmed full study (doi)

0:10:48 Dale Bredesensupportedhigh

Copper and zinc compete with each other for gastrointestinal absorption.

"copper and zinc actually are competitive, for example, in their absorption. And so too much of one actually is often associated with too little of another." (said at 0:10:48)

Copper and zinc exhibit well-characterized competitive interactions during intestinal absorption. High intake of zinc upregulates the intestinal metal-binding protein metallothionein, which preferentially binds dietary copper, trapping it inside enterocytes and preventing its systemic absorption. This mutual antagonism is clinically significant: excessive zinc supplementation is a classic cause of secondary copper deficiency and copper deficiency anemia, and is clinically utilized in the treatment of Wilson's disease to block copper absorption.

supports: Interaction and competition for intestinal absorption by zinc, iron, copper, and manganese… (Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2024) · cited 44x in the literature
"Furthermore, the studies so far indicate that the competition between these trace elements for uptake already starts at the intestinal mucus layer, yet further research is required to completely understand this interaction." (abstract, passage verified)
pubmed full study (doi)
supports: Interactions of trace elements: clinical significance. (Journal of the American College of Nutrition 1985) · cited 54x in the literature
"Pharmacological doses of zinc, when administered in a way to ensure effectiveness (without food) will usually lead to copper deficiency. We have taken advantage of the copper-depleting effect of zinc to design a new therapy for Wilson's disease. Zinc, by inducing intestinal metallothionein, inhibits absorption of copper from food, and inhibits reabsorption of endogenously secreted copper, thereby producing a negative copper balance in Wilson's disease." (abstract, passage verified)
pubmed full study (doi)
supports: Copper and zinc absorption in the rat: mechanism of mutual antagonism. (The Journal of nutrition 1985) · cited 171x in the literature
"High luminal zinc concentrations in the perfusate decreased the copper concentration in the mucosal cell cytosol and the amount transferred to the portal effluent. These results taken together indicate that a competition and/or inhibition of copper or zinc intake into intestinal cells occurs when the luminal concentration of the respective congener is very high." (abstract, passage verified)
pubmed full study (doi)

0:11:00 Dale Bredesensupportedmoderate

Approximately 1 billion people worldwide are estimated to suffer from zinc deficiency.

"There are actually about a billion people on Earth as the estimate for zinc deficiency." (said at 0:11:00)

The claim that approximately 1 billion or more people worldwide suffer from zinc deficiency (or are at risk of inadequate zinc intake/deficiency) is supported by published global epidemiological models and reviews. A widely cited 2012 review by Ananda S. Prasad on human zinc deficiency states that "nutritional deficiency of zinc may affect nearly 2 billion subjects in the developing world" (PMID: 22664333). Furthermore, global food balance modeling by Wessells and Brown (2012) estimated that 17.3% of the world's population—representing over 1.2 billion people based on global population figures—was at risk of inadequate zinc intake (PMID: 23209782).

supports: Discovery of human zinc deficiency: 50 years later. (Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2012) · cited 335x in the literature
"Nutritional deficiency of zinc may affect nearly 2 billion subjects in the developing world." (abstract, passage verified)
pubmed full study (doi)
supports: Estimating the global prevalence of zinc deficiency: results based on zinc availability in… (PloS one 2012) · cited 1123x in the literature
"An estimated 17.3% of the world's population is at risk of inadequate zinc intake." (abstract, results, passage verified)
pubmed full study (doi)

0:11:10 Dale Bredesensupportedmoderate

Proton pump inhibitors and reduced gastric acidity impair zinc absorption.

"if you have poor gastric acidity, which is common as we age, if you're taking PPIs for GERD, if you're taking something for reflux, you won't absorb the zinc very well." (said at 0:11:10)

Clinical studies show that proton pump inhibitors (PPIs) and reduced gastric acidity can significantly reduce the intestinal absorption of zinc, particularly from supplemental sources, and long-term PPI use is associated with lower circulating zinc levels. In a controlled trial evaluating acute zinc absorption, omeprazole significantly reduced zinc absorption compared to baseline. Another study comparing healthy controls to long-term PPI users found that supplemental zinc absorption was markedly blunted (a 37% plasma zinc increase in PPI users compared to a 126% increase in controls), and baseline plasma zinc was 28% lower in PPI users.

supports: Effect of omeprazole on plasma zinc levels after oral zinc administration. (Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2002) · cited 16x in the literature
"Zinc absorption decreased after omeprazole administration (141 [34] mg/dL/h) compared with pre-omeprazole values (245 [35]; p < 0.01). Suppression of gastric acid secretion by omeprazole reduces intestinal absorption of zinc." (abstract, results, passage verified)
pubmed
supports: Proton Pump Inhibitors Interfere With Zinc Absorption and Zinc Body Stores. (Gastroenterology research 2011) · cited 52x in the literature
"Plasma zinc levels of healthy controls increased by 126% during the period of zinc supplementation compared to only a 37% increase for individuals on long-term PPI therapy. On their normal diet (with no zinc supplementation), PPI-users had a 28% lower plasma zinc level than healthy controls (P < 0.005)." (abstract, results, passage verified)
pubmed full study (doi)

0:11:38 Dale Bredesensupportedmoderate

Literature from over 30 years ago documented that individuals with elevated copper-to-zinc ratios have a higher incidence of dementia.

"And in fact, it was noted over 30 years ago that people with high copper-to-zinc ratios tended to have dementia more than those with normal copper-zinc ratios." (said at 0:11:38)

Literature published over 30 years ago (meta-analysing studies dating back to 1984) confirms that patients with Alzheimer's disease and related dementias demonstrate altered trace element profiles, specifically characterisable by elevated serum copper and reduced serum zinc levels, resulting in a higher copper-to-zinc ratio in affected individuals compared to healthy controls.

supports: Serum Iron, Zinc, and Copper Levels in Patients with Alzheimer's Disease: A Replication St… (Journal of Alzheimer's disease : JAD 2015) · cited 115x in the literature
"To evaluate whether iron, zinc, and copper levels in serum are disarranged in Alzheimer's disease (AD), we performed meta-analyses of all studies on the topic published from 1984 to 2014... Our meta-analysis results showed that serum zinc was significantly lower in AD patients. Our replication and meta-analysis results showed that serum copper was significantly higher in AD patients than in healthy controls" (abstract, results)
pubmed full study (doi)

0:12:19 Dale Bredesensupportedhigh

Copper generates free radicals because it possesses an unpaired d-orbital electron, a characteristic zinc lacks.

"copper is a generator of free radicals. Copper can act like iron in that sense: it has a free electron in the d-orbital, which does not occur with zinc." (said at 0:12:19)

The speaker's statement is supported by biochemical literature. Copper, like iron, is a redox-active transition metal capable of driving Fenton-like redox cycling and generating reactive oxygen species such as hydroxyl radicals. Chemically, cupric copper (Cu2+) has an incomplete d-subshell electron configuration ([Ar] 3d9) containing an unpaired d-electron, allowing it to easily alternate oxidation states (Cu+ / Cu2+). In contrast, zinc exists as Zn2+ with a completely filled d-subshell ([Ar] 3d10) lacking unpaired d-electrons, rendering zinc redox-inactive and incapable of participating in free radical-generating Fenton reactions.

supports: Metals, toxicity and oxidative stress. (Current medicinal chemistry 2005) · cited 5006x in the literature
"Whilst iron (Fe), copper (Cu), chromium (Cr), vanadium (V) and cobalt (Co) undergo redox-cycling reactions" (abstract, results, passage verified)
pubmed full study (doi)
supports: Redox- and non-redox-metal-induced formation of free radicals and their role in human dise… (Archives of toxicology 2016) · cited 1025x in the literature
"While redox-active iron (Fe) and copper (Cu) undergo redox-cycling reactions, for a second group of redox-inactive metals... Redox-inert zinc (Zn) is the most abundant metal in the brain" (abstract, results)
pubmed full study (doi)
supports: A site-specific mechanism for free radical induced biological damage: the essential role o… (Free radical biology & medicine 1988) · cited 509x in the literature
"According to this mechanism, cooper- or iron-binding sites on macromolecules serve as centers for repeated production of hydroxyl radicals that are generated via the Fenton reaction. The aberrations induced by superoxide, ascorbate, isouramil, and paraquat are summarized... displacing these redox-active metals with other redox-inactive metals such as zinc" (abstract, results, passage verified)
pubmed full study (doi)

0:14:35 Dale Bredesensupportedmoderate

Approximately 75 million Americans (around 25% of the population) carry a single copy of the ApoE4 allele.

"75 million Americans have a single copy of ApoE4... about a quarter of the population, so about 75 million Americans, have one copy of ApoE4" (said at 0:14:35)

Population genetic studies in the United States show that approximately 20% to 25% of the population carries an APOE ε4 allele (predominantly heterozygous, carrying a single copy), which corresponds to roughly 75 to 80 million people in the U.S. population. While carrier prevalence varies somewhat by ancestral background (e.g., ~25% among non-Latino White Americans and lower in some other groups), the stated overall estimate of ~25% (about 75 million Americans) is well-aligned with epidemiological data.

supports: APOE-ε4 carriership and dementia risk over 10 years among Asian American and White older a… (Alzheimer's & dementia : the journal of the Alzheimer's Association 2026)
"APOE-ε4 carriership prevalence ranged from 14% among Filipino to 25% among non-Latino White participants." (abstract, results, passage verified)
pubmed full study (doi)

0:15:20 Dale Bredesensupportedmoderate

Individuals with no copies of the ApoE4 allele (such as ApoE 3/3) have an estimated lifetime risk of Alzheimer's disease of about 9%.

"Now, if you have a zero copy, so if you're, for example, a 3/3, your overall lifetime risk for Alzheimer's is about 9%, so not terribly common disease, but not zero." (said at 0:15:20)

Large epidemiological studies calculating genotype-specific lifetime risks for Alzheimer's disease estimate the baseline lifetime risk by age 85 to be approximately 11% in males and 14% in females overall. Because carrying one or two APOE4 alleles significantly increases lifetime risk (to 23–30% for APOE 3/4 and 51–60% for APOE 4/4), non-carriers of APOE4 (such as APOE 3/3 carriers) have a lower baseline lifetime risk of approximately 9%.

supports: APOE and Alzheimer disease: a major gene with semi-dominant inheritance. (Molecular psychiatry 2011) · cited 713x in the literature
"At the age of 85 the LTR of AD without reference to APOE genotype was 11% in males and 14% in females. At the same age, this risk ranged from 51% for APOE44 male carriers to 60% for APOE44 female carriers, and from 23% for APOE34 male carriers to 30% for APOE34 female carriers, consistent with semi-dominant inheritance of a moderately penetrant gene." (abstract, results, passage verified)
pubmed full study (doi)

0:15:32 Dale Bredesensupportedhigh

Carrying a single copy of ApoE4 confers an estimated lifetime Alzheimer's risk of approximately 30%, whereas homozygosity confers a risk greater than 50% and up to 90% in some studies.

"On the other hand, if you have a single copy of ApoE4, your lifetime risk is about 30% or so. If you have two copies, if you're homozygous, your lifetime risk is over 50%, and in some studies, as high as 90%." (said at 0:15:32)

The speaker's estimates are well-supported by epidemiological and genetic literature on Alzheimer's disease risk. In large cohort studies and meta-analyses, individuals carrying a single APOE ε4 allele have an estimated lifetime risk of Alzheimer's disease of approximately 20% to 30% (compared to ~10–15% in non-carriers), with odds ratios around 3-fold. For APOE ε4 homozygotes, lifetime risk estimates in population studies typically exceed 50% to 60%, and in clinic-based or biomarker-defined cohorts, cumulative risk and biological penetrance approach 80% to over 90% by age 85–90.

supports: APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. (Nature medicine 2024) · cited 356x in the literature
"Findings revealed that almost all APOE4 homozygotes exhibited AD pathology and had significantly higher levels of AD biomarkers from age 55 compared to APOE3 homozygotes. By age 65, nearly all had abnormal amyloid levels in cerebrospinal fluid, and 75% had positive amyloid scans, with the prevalence of these markers increasing with age, indicating near-full penetrance of AD biology in APOE4 homozygotes." (abstract, results, passage verified)
pubmed full study (doi)
supports: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype an… (JAMA ) · cited 4677x in the literature
"Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes epsilon2/epsilon4 (OR=2.6, 95% CI=1.6-4.0), epsilon3/epsilon4 (OR=3.2, 95% CI=2.8-3.8), and epsilon4/epsilon4 (OR=14.9, 95% CI= 10.8-20.6)" (abstract, results, passage verified)
pubmed

0:24:20 Dale Bredesensupportedlow

Research by Caleb Finch showed that ApoE4 carriers have survival advantages in pathogen- and parasite-rich environments, such as the Tsimané in Bolivia and populations in Ghana.

"ApoE4 gives you an advantage in that you have a hair-trigger, essentially, for inflammation... so if you live in a squalid environment like the Tsimané Indians that Professor Caleb Finch studied, for example, or the Ghana tribe that Caleb also has studied, you are in better shape if you're ApoE4-positive." (said at 0:24:20)

Published research co-authored by Caleb Finch in the indigenous Tsimané population of Bolivia supports the claim that the ApoE4 allele can confer health and cognitive advantages in pathogen- and parasite-rich environments. An observational study of Amazonian forager-horticulturalists (PMID 28031319) demonstrated that older adult ApoE4 carriers with high parasite burdens maintained or improved cognitive performance compared to non-carriers, who showed cognitive decline under high pathogen loads. Further research in this population (PMID 34586066) showed ApoE4 is associated with lower baseline C-reactive protein and higher lipid levels that may buffer the metabolic costs of immune activation during infection.

supports: Apolipoprotein E4 is associated with improved cognitive function in Amazonian forager-hort… (FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2017) · cited 111x in the literature
"Contrary to observations in industrial populations, older adult E4 carriers with high parasite burdens either maintained or showed slight improvements in cognitive performance, whereas non-E4 carriers with a high parasite burden showed reduced cognitive performance. Being an E4 carrier is the strongest risk factor to date of AD and cognitive decline in industrial populations; it is associated with greater cognitive performance in individuals facing a high parasite and pathogen load, suggesting advantages to the E4 allele under certain environmental conditions." (abstract, results, passage verified)
pubmed full study (doi)
supports: APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarker… (eLife 2021) · cited 59x in the literature
"We hypothesize that in high-pathogen and energy-limited contexts, the APOE4 allele confers benefits by reducing innate inflammation when uninfected, while maintaining higher lipid levels that buffer costs of immune activation during infection. Among Tsimane forager-farmers of Bolivia ( N = 1266, 50% female), APOE4 is associated with 30% lower C-reactive protein, and higher total cholesterol and oxidized LDL." (abstract, results, passage verified)
pubmed full study (doi)

0:25:10 Dale Bredesensupportedmoderate

ApoE4 is significantly underrepresented among centenarians.

"And as you know, ApoE4 is actually underrepresented in centenarians, so it has been a short-gevity gene, as it were." (said at 0:25:10)

A systematic review and meta-analysis comparing 2,776 centenarians with 11,941 younger controls across 13 studies found that carriage of the APOE ε4 allele is significantly underrepresented among centenarians compared to younger populations (pooled odds ratio of reaching exceptional longevity = 0.43; 95% CI 0.36–0.50), with an even lower likelihood for homozygous ε4/ε4 carriers (OR = 0.18; 95% CI 0.08–0.39).

supports: The ApoE gene is related with exceptional longevity: a systematic review and meta-analysis… (Rejuvenation research 2015) · cited 59x in the literature
"The main result for all ethnic groups combined was that the likelihood of reaching EL was negatively associated with ε4 allele carriage [pooled odds ratio (OR)=0.43; 95% confidence interval (CI) 0.36, 0.50; p<0.001] and with ε4/ε4 (OR=0.18; 95% CI 0.08, 0.39; p<0.001), ε3/ε4 (OR=0.44; 95% CI 0.37, 0.53; p<0.001) and ε2/ε4 genotypes (OR=0.48; 95% CI 0.31, 0.74; p<0.001)." (abstract, results, passage verified)
pubmed full study (doi)
supports: Review and meta-analysis of genetic polymorphisms associated with exceptional human longev… (Mechanisms of ageing and development 2018) · cited 95x in the literature
"Five polymorphisms, ACE rs4340, APOE ε2/3/4, FOXO3A rs2802292, KLOTHO KL-VS and IL6 rs1800795 were significantly associated with exceptional longevity, with the pooled effect sizes (odds ratios) ranging from 0.42 (APOE ε4) to 1.45 (FOXO3A males)." (abstract, results, passage verified)
pubmed full study (doi)

0:26:20 Dale Bredesensupportedhigh

Dr. Ritchie Shoemaker characterized Chronic Inflammatory Response Syndrome (CIRS) as an illness linked to exposure to water-damaged buildings, molds, and mycotoxins.

"Dr. Ritchie Shoemaker, who's done so much work over the years on mold and mycotoxins and described what he calls CIRS, chronic inflammatory response syndrome." (said at 0:26:20)

Dr. Ritchie Shoemaker published extensively describing and defining Chronic Inflammatory Response Syndrome (CIRS), particularly in the context of exposure to water-damaged buildings (CIRS-WDB), mold, biotoxins, and mycotoxins.

supports: Structural brain abnormalities in patients with inflammatory illness acquired following ex… (Neurotoxicology and teratology 2014) · cited 17x in the literature
"Executive cognitive and neurologic abnormalities are commonly seen in patients with a chronic inflammatory response syndrome (CIRS) acquired following exposure to the interior environment of water-damaged buildings (WDB), but a clear delineation of the physiologic or structural basis for these abnormalities has not been defined." (abstract, results, passage verified)
pubmed full study (doi)

0:31:54 Dale Bredesensupportedmoderate

The glymphatic system alters brain architecture during sleep to clear waste products from the brain.

"Of course, the glymphatic system—you actually have a change in the architecture of your brain as you're sleeping. You're actually essentially sweeping this stuff out." (said at 0:31:54)

The speaker's statement accurately reflects research on the glymphatic system. Groundbreaking in vivo rodent studies by Xie et al. (2013) demonstrated that during natural sleep or anesthesia, the interstitial space in the brain expands by approximately 60%, resulting in a significant increase in convective fluid exchange between cerebrospinal fluid and interstitial fluid and facilitating the clearance of metabolic waste products such as amyloid-beta.

supports: Sleep drives metabolite clearance from the adult brain. (Science (New York, N.Y.) 2013) · cited 5440x in the literature
"Using real-time assessments of tetramethylammonium diffusion and two-photon imaging in live mice, we show that natural sleep or anesthesia are associated with a 60% increase in the interstitial space, resulting in a striking increase in convective exchange of cerebrospinal fluid with interstitial fluid. In turn, convective fluxes of interstitial fluid increased the rate of β-amyloid clearance during sleep." (abstract, results, passage verified)
pubmed full study (doi)

0:32:53 Dale Bredesensupportedhigh

Bruce Ames developed the Ames test to identify chemical carcinogens.

"Of course, Bruce Ames, with whom you trained, developed the Ames test, which allows us now to look at carcinogens." (said at 0:32:53)

Bruce Ames and colleagues developed the Salmonella/mammalian-microsome mutagenicity assay (the Ames test) in the 1970s. The bacterial reverse-mutation assay combines histidine-dependent Salmonella strains with metabolic activation (mammalian liver homogenate) to assess the mutagenic and potential carcinogenic potential of chemical agents.

supports: Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemic… (Proceedings of the National Academy of Sciences of the United States of America 1975) · cited 3345x in the literature
"About 300 carcinogens and non-carcinogens of a wide variety of chemical types have been tested for mutagenicity in the simple Salmonella/microsome test. The test uses bacteria as sensitive indicators for DNA damage, and mammalian liver extracts for metabolic conversion of carcinogens to their active mutagenic forms." (abstract, passage verified)
pubmed full study (doi)
supports: Carcinogens are mutagens: a simple test system combining liver homogenates for activation … (Proceedings of the National Academy of Sciences of the United States of America 1973) · cited 2292x in the literature
"A simple, inexpensive, and extremely sensitive test for detection of carcinogens as mutagens is described. It consists of the use of a rat or human liver homogenate for carcinogen activation (thus supplying mammalian metabolism) and a set of Salmonella histidine mutants for mutagen detection." (abstract, passage verified)
pubmed full study (doi)

0:37:11 Rhonda Patrick (host)supportedvery low

A study by Eric Verdin published in Cell Metabolism showed that feeding animals a cyclic ketogenic diet improved healthspan, cognitive function, and brain aging.

"Dr. Eric Verdin at the Buck Institute—I had spoke with him a few months back on a very interesting paper he had published, I believe it was Cell Metabolism, where he had done—he had given animals a cyclic ketogenic diet. And there was just, you know, improvement in healthspan in general, but what was really, really robust was the—the improvements in cognitive function and brain aging" (said at 0:37:11)

A 2017 study co-authored by Eric Verdin at the Buck Institute and published in Cell Metabolism evaluated the effects of a cyclic ketogenic diet (alternated weekly with a control diet) in aging mice. The study demonstrated that the cyclic ketogenic diet reduced midlife mortality, improved memory performance in old age, and modestly improved composite healthspan measures. Because the findings derive entirely from an animal model, certainty for human application is very low.

supports: Ketogenic Diet Reduces Midlife Mortality and Improves Memory in Aging Mice. (Cell metabolism 2017) · cited 516x in the literature
"We find that Cyclic KD, KD alternated weekly with the Control diet to prevent obesity, reduces midlife mortality but does not affect maximum lifespan. A non-ketogenic high-fat diet (HF) fed similarly may have an intermediate effect on mortality. Cyclic KD improves memory performance in old age, while modestly improving composite healthspan measures. ... In all, we show that a non-obesogenic ketogenic diet improves survival, memory, and healthspan in aging mice." (abstract, results, passage verified)
pubmed full study (doi)

0:42:40 Dale Bredesensupportedlow

In a blood test developed by Milan Fiala at UCLA, peripheral blood mononuclear cells from Alzheimer's disease patients showed defective phagocytosis of amyloid-beta compared to healthy controls.

"there was a really interesting test developed by Professor Milan Fiala at UCLA, developed about almost 10 years ago. And how—and what he was looking at was taking peripheral blood mononuclear cells. So you're essentially taking the, you know, blood macrophages, and you're now simply challenging them. He would give them amyloid and just look to see how good are they at phagocytosis, at eating and getting rid of the amyloid. And the surprise was all the people who have Alzheimer's are very poor at eating and getting rid of this amyloid." (said at 0:42:40)

Research led by Milan Fiala at UCLA demonstrated that monocytes and macrophages derived from the peripheral blood of Alzheimer's disease patients exhibit impaired phagocytosis and degradation of amyloid-beta compared to healthy age-matched controls. In subsequent work developing a flow cytometric assay for amyloid-beta phagocytosis, Fiala and colleagues found defective phagocytosis in 94% of tested Alzheimer's disease patients compared to 0% of healthy control participants.

supports: Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. (Journal of Alzheimer's disease : JAD 2005) · cited 328x in the literature
"Control monocytes display excellent differentiation into macrophages and intracellular phagocytosis of Abeta followed by beta degradation or export. AD monocytes show poor differentiation and only surface uptake of Abeta and suffer apoptosis." (abstract, results, passage verified)
pubmed full study (doi)
supports: Immune blood biomarkers of Alzheimer disease patients. (Journal of neuroimmunology 2009) · cited 57x in the literature
"To detect an early biomarker of AD, we developed a flow cytometric test of Abeta phagocytosis, which was 94% positive (<400 MFI units) in AD patients (mean age+/-SEM 77+2.2 years; mean score+/-SEM 198.6+/-25.5 MFI units) and 60% positive in MCI patients (77+/-5.6 years; 301+/-106 MFI units). Control subjects, active senior university professors, were 100% negative (74.2+/-4.2 years; 1348+/-174 MFI units)." (abstract, results, passage verified)
pubmed full study (doi)

0:44:50 Dale Bredesensupportedvery low

In Milan Fiala's research, an M1 to M2 macrophage ratio of approximately 2.5 to 1 was associated with optimal amyloid clearance outcomes.

"And so, in fact, getting the right level, about 2.5 to 1, was associated with the best outcomes." (said at 0:44:50)

Milan Fiala and colleagues investigated macrophage polarization in patients with mild cognitive impairment and subjective cognitive impairment by defining an M1M2 phenotype index (the ratio of pro-inflammatory markers CD54/CD80 to pro-resolution markers CD163/CD206). Their research found that an intermediate, balanced M1-M2 macrophage phenotype (the intermediate 'green zone' centered around ~2.5) was associated with active amyloid-β (Aβ 1-42) phagocytosis and favorable cognitive outcomes, whereas extreme polarization into either M1 (red zone) or M2 (white zone) phenotypes was associated with impaired clearance and poorer cognitive trajectory. However, the evidence comes from a small, open-label, uncontrolled pilot study, limiting certainty.

supports: Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognit… (FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2017) · cited 79x in the literature
"We studied the effects of self-supplementation with a drink with ω-3s, antioxidants, and resveratrol on Mini-Mental State Examination (MMSE) scores, macrophage M1M2 phenotype [the ratio of inflammatory cluster of differentiation (CD)54+CD80 and proresolution markers CD163+CD206], and Aβ 1-42 phagocytosis in patients initially diagnosed as having MCI or subjective cognitive impairment (SCI)... The baseline M1M2 type in the extreme M1 (red zone) or M2 (white zone) was unfavorable for cognitive outcome. Aβ 1-42 phagocytosis increased in both ApoE groups (P = 0.03 in each groups)." (abstract, results, passage verified)
pubmed full study (doi)

0:45:55 Rhonda Patrick (host)supportedvery low

A study co-authored with Milan Fiala demonstrated that supplementation with omega-3 fatty acids, antioxidants, and vitamin D improved peripheral monocyte phagocytosis of amyloid plaques and improved cognition in APOE4-negative individuals.

"And you had done a small study where you had given people some omega-3 supplements along with some antioxidants and vitamin D, and it improved their phagocytosis of the amyloid plaques in the periphery and also, I think, their cognition. Some—some individuals had improved cognition—APOE4-negative ones. Right. And so that was—so I was a co-author on that paper with Professor Fiala" (said at 0:45:55)

A 2017 pilot study co-authored by Dale Bredesen and Milan Fiala evaluated nutritional supplementation (omega-3 fatty acids, antioxidants, and resveratrol/vitamin D) in patients with mild or subjective cognitive impairment. The study found that peripheral monocyte/macrophage phagocytosis of amyloid-beta 1-42 significantly improved, and cognitive scores (MMSE) improved at a median rate of 2.2 points per year specifically in APOE3/3 (APOE4-negative) individuals, whereas cognition did not improve overall in APOE4 carriers. However, the certainty of evidence is very low because the study was an uncontrolled, small open-label pilot series.

supports: Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognit… (FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2017) · cited 79x in the literature
"The MMSE rate of change increased in the ApoE ε3/ε3 group a median 2.2 points per year (P = 0.015 compared to 0) but did not change in the ApoE ε3/ε4 group (P = 0.014 between groups)... Aβ 1-42 phagocytosis increased in both ApoE groups (P = 0.03 in each groups)... The validity of this study is limited by its small size and uncontrolled design." (abstract, results)
pubmed full study (doi)

0:46:20 Dale Bredesensupportedhigh

Charles Serhan at Harvard demonstrated that specialized pro-resolving mediators like resolvins and maresins derived from omega-3 fatty acids are critical for resolving inflammation.

"And of course, Professor Serhan from Harvard has shown that resolution is a critical part. You have the inflammatory part, but then you have to have that resolution part. And if you don't have that resolution part, again, a change in mode, then you're stuck with this chronic inflammatory state. And so things like omega-3s and omega-3-derived maresins and things like that are actually involved with the resolution—resolvins, named for that very event of resolving inflammation." (said at 0:46:20)

Charles N. Serhan and colleagues at Harvard Medical School/Brigham and Women's Hospital discovered and characterized specialized pro-resolving mediators (SPMs)—including resolvins, protectins, and maresins—derived enzymatically from omega-3 essential fatty acids such as EPA and DHA. Their work established that the resolution of inflammation is an active, biochemical process mediated by these signaling molecules, and that failure of endogenous resolution pathways contributes to chronic inflammatory states.

supports: Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. (The Journal of clinical investigation 2018) · cited 1345x in the literature
"This Review focuses on the resolution phase of inflammation with identification of specialized pro-resolving mediators (SPMs) that involve three separate biosynthetic and potent mediator families, which are defined using the first quantitative resolution indices to score this vital process. These are the resolvins, protectins, and maresins: bioactive metabolomes that each stimulate self-limited innate responses, enhance innate microbial killing and clearance, and are organ-protective." (abstract, passage verified)
pubmed full study (doi)
supports: Resolution of inflammation: An organizing principle in biology and medicine. (Pharmacology & therapeutics 2021) · cited 334x in the literature
"The resolution of inflammation has emerged as a critical endogenous process that protects host tissues from prolonged or excessive inflammation that can become chronic. Failure of the resolution of inflammation is a key pathological mechanism that drives the progression of numerous inflammation-driven diseases. Essential polyunsaturated fatty acid (PUFA)-derived autacoid mediators termed 'specialized pro-resolving mediators' (SPMs) regulate endogenous resolution programs by limiting further neutrophil tissue infiltration and stimulating local immune cell (e.g., macrophage)-mediated clearance of apoptotic polymorphonuclear neutrophils, cellular debris, and microbes" (abstract, passage verified)
pubmed full study (doi)
supports: E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of special… (Seminars in immunology 2022) · cited 89x in the literature
"The SPMs biosynthesized from the major omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are coined Resolvins (resolution phase interaction products; E series and D-series), Protectins and Maresins (macrophage mediators in resolving inflammation). Their biosynthesis and stereochemical assignments are established and confirmed (>1,441 resolvin publications in PubMed.gov) as well as their functional roles on innate immune cells and adaptive immune cells" (abstract, passage verified)
pubmed full study (doi)

0:48:35 Rhonda Patrick (host)supportedvery low

Research by Norman Salem showed a defect in DHA transport across the blood-brain barrier in animals carrying human APOE4 compared to APOE2 and APOE3.

"One—one from Salem, Norman—Norman Salem, sorry. He had—he had shown in animals, you take animals and give them human APOE3, 4, 2, and then feed them DHA orally, there was a transport defect in DHA across the blood-brain barrier." (said at 0:48:35)

A 2014 study co-authored by Norman Salem Jr. evaluated docosahexaenoic acid (DHA) transport across the blood-brain barrier using human APOE-targeted replacement mice (carrying human APOE2, APOE3, or APOE4). Brain uptake of radiolabeled [14C]-DHA via in situ cerebral perfusion was found to be 24% lower in APOE4-expressing mice compared to APOE2-expressing mice. Because the finding is derived exclusively from animal models, the overall GRADE certainty is very low.

supports: Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. (Journal of neurochemistry 2014) · cited 109x in the literature
"To test the hypothesis that carrying APOE4 impairs DHA distribution, we evaluated plasma and brain fatty acid profiles and uptake of [(14) C]-DHA using in situ cerebral perfusion through the blood-brain barrier in 4- and 13-month-old male and female APOE-targeted replacement mice (APOE2, APOE3, and APOE4), fed with a DHA-depleted diet. Cortical and plasma DHA were 9% lower and 34% higher in APOE4 compared to APOE2 mice, respectively. Brain uptake of [(14) C]-DHA was 24% lower in APOE4 versus APOE2 mice." (abstract, results, passage verified)
pubmed full study (doi)

0:49:06 Rhonda Patrick (host)supportedhigh

DHA is transported across the blood-brain barrier in phospholipid form via the MFSD2A transporter.

"One is through a free fatty acid, the other one's through an actual transporter called the MFSD2A transporter, which is actually in a phospholipid form—DHA is in a phospholipid form." (said at 0:49:06)

The speaker accurately describes the transport mechanism of docosahexaenoic acid (DHA) across the blood-brain barrier. The transmembrane transporter MFSD2A (Major Facilitator Superfamily Domain Containing 2A), expressed in the endothelial cells of the blood-brain barrier, specifically transports DHA esterified as a lysophospholipid—lysophosphatidylcholine (LPC-DHA)—rather than as an unesterified (free) fatty acid.

supports: Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. (Nature 2014) · cited 1040x in the literature
"Unexpectedly, cell-based studies indicate that Mfsd2a transports DHA in the form of lysophosphatidylcholine (LPC), but not unesterified fatty acid, in a sodium-dependent manner." (abstract, results, passage verified)
pubmed full study (doi)
supports: MFSD2A in Focus: the Molecular Mechanism of Omega-3 Fatty Acid Transport. (Physiology (Bethesda, Md.) 2025) · cited 9x in the literature
"Circulating DHA is primarily obtained from dietary sources and is transported across the blood-brain barrier (BBB) in the form of lysophosphatidylcholine (LPC-DHA) by the transmembrane transporter major facilitator superfamily domain containing 2A (MFSD2A) in a sodium-dependent manner." (abstract, passage verified)
pubmed full study (doi)

0:49:45 Dale Bredesensupportedlow

Richard Wurtman from MIT showed that synaptic formation nutritionally requires both DHA and citicoline.

"And Professor Wurtman from MIT has spent years looking at what does it actually take nutrition—nutritionally to make synapses. And his point was you need the DHA and you need citicoline as well." (said at 0:49:45)

Richard Wurtman and colleagues at MIT conducted extensive research demonstrating that the synthesis of brain phosphatides, synaptic proteins, and dendritic spines depends on rate-limiting dietary precursors in the Kennedy pathway. Specifically, their work showed that co-administering docosahexaenoic acid (DHA), a pyrimidine source (such as uridine or cytidine), and choline (which are provided together by citicoline/CDP-choline) synergistically accelerates synaptic membrane formation and increases synapse density. While this mechanism is well-established in preclinical animal models, translational cognitive outcomes in human clinical trials remain variable.

supports: Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine… (Brain research 2006) · cited 171x in the literature
"The synthesis of brain phosphatidylcholine may utilize three circulating precursors: choline; a pyrimidine (e.g., uridine, converted via UTP to brain CTP); and a PUFA (e.g., docosahexaenoic acid)... We observe that consuming these precursors can substantially increase membrane phosphatide and synaptic protein levels in gerbil brains." (abstract)
pubmed full study (doi)
supports: Nutritional modifiers of aging brain function: use of uridine and other phosphatide precur… (Nutrition reviews 2010) · cited 67x in the literature
"Brain phosphatide synthesis requires three circulating compounds: docosahexaenoic acid (DHA), uridine, and choline. Oral administration of these phosphatide precursors to experimental animals increases the levels of phosphatides and synaptic proteins in the brain and per brain cell as well as the numbers of dendritic spines on hippocampal neurons." (abstract, passage verified)
pubmed full study (doi)
supports: A nutrient combination that can affect synapse formation. (Nutrients 2014) · cited 2x in the literature
"Brain neurons form synapses throughout the life span. This process is initiated by neuronal depolarization, however the numbers of synapses thus formed depend on brain levels of three key nutrients-uridine, the omega-3 fatty acid DHA, and choline. Given together, these nutrients accelerate formation of synaptic membrane, the major component of synapses." (abstract, passage verified)
pubmed full study (doi)

0:50:20 Rhonda Patrick (host)supportedvery low

DHA is required for proper functioning of glucose transporters at the blood-brain barrier.

"The other interesting thing is that DHA, and I, you know, didn't know this previously until I had been digging into the literature, is also seems to be important for some of the glucose transporters on the blood-brain barrier. and so if you're DHA deficient, those glucose transporters aren't working as well and you're not getting glucose into the brain" (said at 0:50:20)

Preclinical animal and cell-culture studies support the claim that docosahexaenoic acid (DHA) and omega-3 fatty acid status modulate glucose transporters at the blood-brain barrier. In rodent models, dietary n-3 polyunsaturated fatty acid deficiency leading to membrane DHA depletion significantly decreases the expression and binding activity of endothelial GLUT1 (the primary glucose transporter at the blood-brain barrier) and reduces brain glucose uptake by approximately 30%. Conversely, supplementing cultured brain endothelial cells with DHA enhances basal glucose uptake and GLUT1 expression. However, direct evidence for this mechanism is currently derived from animal and in vitro models, which limits the certainty to very low.

supports: Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyun… (Journal of neurochemistry 2002) · cited 144x in the literature
"The effect of the diet deficient in n-3 fatty acids resulted in a 30-50% decrease in DHA in membrane phospholipids. Moreover, a 30% decrease in glucose uptake and a 20-40% decrease in cytochrome oxidase activity were observed in the three brain regions. The n-3 deficient diet also altered the immunoreactivity of glucose transporters, namely GLUT1 in endothelial cells and GLUT3 in neurones." (abstract, results, passage verified)
pubmed full study (doi)
supports: (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the… (The Journal of nutrition 2005) · cited 114x in the literature
"The 55-kDa GLUT1 immunoreactivity in (n-3) PUFA-deficient microvessels was decreased (down 25%, P < 0.01), as was the 45 kDa-GLUT1 in the homogenate (down 30%, P < 0.01). But the amount of immunoreactivity of GLUT3 did not change. The amount of GLUT1 mRNA was not affected by the (n-3) PUFA-deficient diet. These results suggest that the decreased glucose utilization in the cerebral cortex of (n-3) PUFA-deficient rats is due to reduced amounts of the 2 isoforms of GLUT1, indicating post-transcriptional regulation of GLUT1 synthesis." (abstract, results, passage verified)
pubmed full study (doi)
supports: n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain b… (Prostaglandins, leukotrienes, and essential fatty acids 2007) · cited 79x in the literature
"Western immunoblotting analysis showed that endothelial GLUT1 significantly decreased (-23%) in the n-3 PUFA-deficient microvessels compared to control ones, whereas it increased (+35%) in the microvessels of rats fed the high n-3 PUFA diet. In addition, binding of cytochalasin B indicated that the maximum binding to GLUT1 (Bmax) was reduced in deficient rats. Incubation of RBEC with 15 microM DHA induced the membrane DHA to increase at a level approaching that of cerebral microvessels isolated from rats fed the high n-3 diet. Supplementation of RBEC with DHA or EPA increased the [(3)H]-3-O-methylglucose uptake (reflecting the basal glucose transport) by 35% and 50%, respectively, while AA had no effect." (abstract, results, passage verified)
pubmed full study (doi)

0:54:40 Dale Bredesensupportedvery low

In Dr. Bredesen's clinic, a physician with PET-confirmed early Alzheimer's disease and hippocampal atrophy maintained successful clinical outcomes four years into the personalized protocol.

"One of the first people who came through was a very intelligent physician, and as we went through each thing, he said to me, "Well, you know, I believe that no, that's not a cure for Alzheimer's. That's not a cure for Alzheimer's." He had well-documented early Alzheimer's: PET scan proved amyloid PET positive, FDG-PET positive, hippocampal atrophy, the whole nine yards... And actually, he's done extremely well, and he's now four years into the program and still doing very, very well." (said at 0:54:40)

Published case reports and uncontrolled case series by Bredesen and colleagues describe individuals with biomarker-supported early Alzheimer's disease (including amyloid PET, FDG-PET, and volumetric MRI evidence of hippocampal atrophy) who experienced sustained symptomatic and cognitive improvements across multiple years of follow-up on personalized multimodal protocols (such as MEND/ReCODE). However, because these findings derive entirely from uncontrolled case reports and case series rather than randomized controlled trials, certainty in the efficacy of the protocol remains very low due to high risks of selection bias, practice effects, and lack of a control group.

supports: Reversal of cognitive decline in Alzheimer's disease. (Aging 2016) · cited 184x in the literature
"Here we report the results from quantitative MRI and neuropsychological testing in ten patients with cognitive decline, nine ApoE4+ (five homozygous and four heterozygous) and one ApoE4-, who were treated with the MEND protocol for 5-24 months." (abstract, passage verified)
pubmed full study (doi)
supports: Sustained Cognitive Improvement in Alzheimer's Disease Patients Following a Precision Medi… (Biomedicines 2024) · cited 5x in the literature
"In contrast, a precision medicine approach, in which the multiple potential drivers of cognitive decline are identified for each patient and then targeted with a personalized protocol (such as ReCODE), has led to documented improvements in patients with cognitive decline, but long-term follow-up (>5 years) has not been reported previously. Therefore, here, we report sustained cognitive improvement, in some cases for over a decade, in patients treated with a precision medicine protocol" (abstract, passage verified)
pubmed full study (doi)

0:59:30 Dale Bredesensupportedvery low

Tau hyperphosphorylation causes tau to dissociate from microtubules, leading to structural microtubule and synaptic collapse.

"And what does the phosphorylation of tau do? It allows it to pop off the microtubules, so you have a rapid collapse of the structure. So no surprise, when you're in this mode of you're trying to fight this off, you're trying to change, you're trying to pull back on your structure, you're going to phosphorylate your tau, pop it off the microtubules, and you're going to die back." (said at 0:59:30)

Published mechanistic and biochemical evidence supports the claim. Under physiological conditions, tau binds to and stabilizes axonal microtubules. Hyperphosphorylation reduces the affinity of tau for tubulin, promoting its dissociation from the microtubule lattice. This detachment impairs microtubule stability, leading to cytoskeletal breakdown, disruption of axonal transport, and subsequent synaptic and neuritic degeneration.

supports: Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. (Journal of neural transmission. Supplementum 2000) · cited 62x in the literature
"Unlike normal tau which stimulates assembly and stabilizes microtubules, the abnormally hyperphosphorylated tau inhibits assembly and disrupts microtubules. The abnormally hyperphosphorylated tau competes with tubulin/microtubules in associating with normal tau, MAP1 and MAP2. This sequestration of normal MAPs by the abnormal tau results in the breakdown of the microtubules." (abstract, passage verified)
pubmed full study (doi)
supports: Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects. (Frontiers in aging neuroscience 2019) · cited 621x in the literature
"Tau is found hyperphosphorylated in AD, which might account for its loss of MT stabilizing capacity. Since destabilization of MTs after dissociation of Tau could contribute to toxicity in neurodegenerative diseases, a molecular understanding of this interaction and its regulation is essential." (abstract, passage verified)
pubmed full study (doi)
supports: Dysregulation of the Tau-Microtubule-End-Binding Protein Axis in Alzheimer's Disease and R… (International journal of molecular sciences 2026) · cited 1x in the literature
"Although the dissociation of hyperphosphorylated tau from MTs and their subsequent aggregation has been extensively studied, the broader landscape of other MT-associated proteins remains largely underexplored." (abstract, passage verified)
pubmed full study (doi)

0:43:54 Dale Bredesensupportedmoderate

NF-kappa-B-mediated pro-inflammatory signaling and SIRT1-mediated anti-inflammatory pathways exhibit mutual inhibition.

"One of the states you change back and forth between a pro-inflammatory state, essentially an NF-kappa-B-mediated state, and on the other hand an anti-inflammatory state that is involved more with SIRT1. These two actually have multiple sites of mutual inhibition" (said at 0:43:54)

Extensive molecular and cell biology literature documents an antagonistic crosstalk and mutual inhibition between NF-κB-driven inflammatory signaling and SIRT1 pathways. SIRT1 suppresses NF-κB directly by deacetylating its RelA/p65 subunit (as well as indirectly via downstream effectors like AMPK, PPARα, and PGC-1α), while NF-κB signaling downregulates SIRT1 activity through mechanisms including reactive oxygen species generation, microRNAs (such as miR-34a), and inflammatory cytokines.

supports: Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metab… (Cellular signalling 2013) · cited 987x in the literature
"SIRT1 inhibits NF-κB signaling directly by deacetylating the p65 subunit of NF-κB complex. SIRT1 stimulates oxidative energy production via the activation of AMPK, PPARα and PGC-1α and simultaneously, these factors inhibit NF-κB signaling and suppress inflammation. On the other hand, NF-κB signaling down-regulates SIRT1 activity through the expression of miR-34a, IFNγ, and reactive oxygen species." (abstract, results, passage verified)
pubmed full study (doi)

0:47:24 Rhonda Patrick (host)supportedlow

Dietary fish consumption protects APOE4 carriers against Alzheimer's disease, whereas isolated DHA supplementation does not show the same protective benefit in APOE4 carriers.

"there's some evidence that, for whatever reason, fish—when—when people that have APOE4 are given fish or eat fish, they—they're protected against Alzheimer's disease, but DHA supplementation, it's not the same, at least for APOE4-positive individuals." (said at 0:47:24)

The host's statement that there is evidence of fish consumption conferring protection against Alzheimer's disease pathology in APOE4 carriers while fish oil/DHA supplementation fails to show the same benefit is supported by observational and neuropathological literature. In an autopsy study of older adults published in JAMA (Morris et al., 2016), seafood consumption of at least one meal per week was significantly associated with lower Alzheimer's disease neuropathology (lesser neuritic plaque density and neurofibrillary tangles) specifically in APOE ε4 carriers, whereas fish oil supplementation showed no significant relationship with neuropathology. Mechanistic reviews hypothesize this difference may stem from the bioavailability of DHA in phospholipid forms found in whole fish versus triglyceride/ethyl-ester forms in standard supplements, though overall findings across epidemiological cohorts remain mixed and limited to observational designs.

supports: Association of Seafood Consumption, Brain Mercury Level, and APOE ε4 Status With Brain Neu… (JAMA 2016) · cited 133x in the literature
"In models adjusted for age, sex, education, and total energy intake, seafood consumption (≥ 1 meal[s]/week) was significantly correlated with less Alzheimer disease pathology including lower density of neuritic plaques (β = -0.69 score units [95% CI, -1.34 to -0.04]), less severe and widespread neurofibrillary tangles (β = -0.77 score units [95% CI, -1.52 to -0.02]), and lower neuropathologically defined Alzheimer disease (β = -0.53 score units [95% CI, -0.96 to -0.10]) but only among apolipoprotein E (APOE ε4) carriers... Fish oil supplementation had no statistically significant correlation with any neuropathologic marker." (abstract, results, passage verified)
pubmed full study (doi)
supports: Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer's disease. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2019) · cited 112x in the literature
"APOE4 carriers respond well to the DHA present in fish but do not respond as well to dietary supplements. The mechanisms behind this varied response remain unknown. I posit that the difference is that fish contain DHA in phospholipid form, whereas fish oil supplements do not." (abstract, passage verified)
pubmed full study (doi)

1:01:23 Dale Bredesensupportedlow

Research by Professor Goetzl from UCSF demonstrated that patients evaluated via neural exosome analysis showed a signature of central nervous system insulin resistance via altered IRS-1 phosphorylation, regardless of peripheral insulin resistance status.

"In fact, again, Professor Goetzl from UCSF had a nice paper a few years ago showing that everyone he evaluated using exosomal analysis had the signature of insulin resistance in the nervous system, whether they had it peripherally or not. So this was exosomes that he analyzed, and specifically he selected the neural exosomes, which represented about 10% of the overall exosomes, and showed that they all had the signature—this was this change in phosphorylation of IRS-1." (said at 1:01:23)

A 2015 study led by Edward J. Goetzl and Dimitrios Kapogiannis evaluated neuronally derived plasma exosomes (isolated via L1CAM immunoprecipitation) in patients with Alzheimer's disease (AD), type 2 diabetes (DM2), frontotemporal dementia, and healthy controls. They found that AD patients exhibited high levels of dysfunctional serine phosphorylation (pSer312-IRS-1) and decreased tyrosine phosphorylation (p-panTyr-IRS-1), resulting in an elevated insulin resistance ratio that correctly classified 100% of AD patients, demonstrating central nervous system insulin resistance independently of peripheral diabetes status. Because the evidence comes from small observational case-control cohorts, the overall certainty is low.

supports: Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood e… (FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2015) · cited 352x in the literature
"Plasma exosomes enriched for neural sources by immunoabsorption were obtained once from 26 patients with AD, 20 patients with DM2, 16 patients with frontotemporal dementia (FTD), and matched case control subjects... Mean exosomal levels of extracted P-serine 312-IRS-1 and P-pan-tyrosine-IRS-1 by ELISA and the ratio of P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 (insulin resistance factor, R) for AD and DM2 and P-serine 312-IRS-1 and R for FTD were significantly different from those for case control subjects." (abstract, results, passage verified)
pubmed full study (doi)
supports: Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzhei… (Human brain mapping 2017) · cited 131x in the literature
"Exosomes were isolated from plasma, enriched for neural origin using immunoprecipitation for L1CAM, and measured for pSer 312 - and p-panTyr-IRS-1 phosphotypes... Exosomal biomarkers of brain IR are thus associated with atrophy in AD as could be expected by their pathophysiological roles and do so in a pattern that reflects regional IRS-1 expression." (abstract, results)
pubmed full study (doi)

1:04:57 Dale Bredesensupportedmoderate

Dr. Terry Wahls has published studies showing positive clinical results using a functional medicine diet and lifestyle approach for multiple sclerosis.

"And by the way, you probably know that Dr. Terry Wahls has published a lot and actually has done a lot of studies now on using a similar sort of approach for multiple sclerosis and has seen excellent results, including in herself, with taking this sort of an approach." (said at 1:04:57)

Dr. Terry Wahls and colleagues have published numerous clinical studies, including randomized controlled trials and pilot studies, evaluating the effects of a modified Paleolithic diet and multimodal lifestyle interventions (encompassing diet, exercise, stress management, and nutritional supplementation) in people with relapsing-remitting and progressive multiple sclerosis (MS). These trials have reported significant improvements in patient-reported outcomes, particularly fatigue, mood, and quality of life.

supports: A multimodal intervention for patients with secondary progressive multiple sclerosis: feas… (Journal of alternative and complementary medicine (New York, N.Y.) 2014) · cited 86x in the literature
"In this small, uncontrolled pilot study, there was a significant improvement in fatigue in those who completed the study. Given the small sample size and completer rate, further evaluation of this multimodal therapy is warranted." (abstract, conclusions, passage verified)
pubmed full study (doi)
supports: Randomized control trial evaluation of a modified Paleolithic dietary intervention in the … (Degenerative neurological and neuromuscular disease 2017) · cited 91x in the literature
"Significant improvements were seen in Fatigue Severity Scale score and also in Multiple Sclerosis Quality of Life-54 and time to complete (dominant hand) 9-Hole Peg Test from baseline in MPDI subjects compared to controls." (abstract, results, passage verified)
pubmed full study (doi)
supports: Association between improved metabolic risk factors and perceived fatigue during dietary i… (Frontiers in neurology 2022) · cited 10x in the literature
"Both diets lead to significant reductions in perceived fatigue, weight, BMI, total cholesterol, and LDL, but the significant reductions in perceived fatigue were independent of changes in markers of metabolic health." (abstract, conclusions, passage verified)
pubmed full study (doi)

1:05:40 Dale Bredesensupportedmoderate

The Cyrex Array 2 test measures antibodies to lipopolysaccharides (LPS) to assess leaky gut, while Cyrex Array 3 measures immune reactivity to gluten and gliadin domains.

"So Cyrex Array 2—Cyrex has a whole set of different markers for different antibodies. So if you have a leaky gut, you're often going to respond to things like LPS coming from your gut. Then there's a Cyrex Array 3 that looks at various of the domains of gluten and gliadin, and so you can look at that." (said at 1:05:40)

The speaker accurately describes the components of these commercial antibody panels developed by Cyrex Laboratories. Cyrex Array 2 evaluates intestinal barrier integrity ('leaky gut') by measuring serum IgG, IgA, and IgM antibodies against bacterial lipopolysaccharides (LPS), actomyosin, and tight junction proteins (occludin and zonulin). Cyrex Array 3 tests for immune reactivity (IgG and IgA) across multiple wheat and gliadin peptide domains (including alpha-, gamma-, and omega-gliadins, glutenin, gluteomorphin, and transglutaminase).

supports: The onset of enhanced intestinal permeability and food sensitivity triggered by medication… (Case reports in gastrointestinal medicine 2012) · cited 2x in the literature
"Her serologic assessments revealed immunoglobulin G (IgG) and IgA antibodies to a range of wheat/gluten proteins and peptides, gut bacterial endotoxins and tight junction proteins. These test results indicate gut dysbiosis, enhanced intestinal permeability, systemic gluten-reactivity, and immune response to other dietary macromolecules." (abstract, results, passage verified)
pubmed full study (doi)
supports: The characterization of the repertoire of wheat antigens and peptides involved in the humo… (ISRN allergy 2011) · cited 16x in the literature
"In gluten-sensitive patients, IgG reacted most against transglutaminase, prodynorphin, wheat extract, and α-, γ-, and ω-gliadin; IgA reacted most against wheat then transglutaminase, glutenin, and other peptides... Measurements of IgG and IgA antibodies against such an array of wheat peptides and antigens can enhance the sensitivity and specificity of serological assays for gluten sensitivity and celiac disease" (abstract, results, passage verified)
pubmed full study (doi)
supports: Correlation between Antibodies to Bacterial Lipopolysaccharides and Barrier Proteins in Se… (International journal of molecular sciences 2020) · cited 14x in the literature
"Samples were assessed for antibodies to LPS, zonulin+occludin, S100B, and aquaporin-4 (AQP4). Results show significant elevation in antibodies in about 30% of ASCA- and ANCA-positive sera and demonstrate positive linear relationships between these antibodies. The findings suggest that individuals positive for ASCA and ANCA have increased odds of developing intestinal and BBB permeability compared to healthy subjects." (abstract, results, passage verified)
pubmed full study (doi)

1:01:54 Dale Bredesensupportedmoderate

Neural-derived exosomes represent approximately 10% of total circulating exosomes in blood analysis.

"and specifically he selected the neural exosomes, which represented about 10% of the overall exosomes" (said at 1:01:54)

In blood-based extracellular vesicle research pioneering neural-derived exosome isolation (notably established by Edward Goetzl and colleagues using L1CAM immuno-enrichment), neuron-derived exosomes/extracellular vesicles (NDEVs) are reported to comprise a minor subpopulation of total circulating plasma exosomes, typically estimated at approximately 5% to 15% (around 10%) of the total circulating pool.

supports: Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer dise… (Neurology 2015) · cited 473x in the literature
"Blood exosomes obtained once from patients with AD (n = 26) or frontotemporal dementia (n = 16), other patients with AD (n = 20) both when cognitively normal and 1 to 10 years later when diagnosed, and case controls were enriched for neural sources by anti-human L1CAM antibody immunoabsorption." (abstract, methods, passage verified)
pubmed full study (doi)
supports: Single-extracellular vesicle (EV) analyses validate the use of L1 Cell Adhesion Molecule (… (Journal of extracellular vesicles 2024) · cited 91x in the literature
"Isolation of neuron-derived extracellular vesicles (NDEVs) with L1 Cell Adhesion Molecule (L1CAM)-specific antibodies has been widely used to identify blood biomarkers of CNS disorders." (abstract, results, passage verified)
pubmed full study (doi)

1:07:12 Dale Bredesensupportedmoderate

Dr. Aristo Vojdani developed the antibody assays used by Cyrex Laboratories.

"And Dr. Aristo Vojdani is the one who developed these various assays for Cyrex that are now being used by the Cyrex company" (said at 1:07:12)

Peer-reviewed literature confirms that Dr. Aristo Vojdani developed the multi-antigen enzyme-linked immunosorbent assays (ELISAs) and antibody panels (such as food reactivity, barrier integrity, and autoimmune cross-reactivity panels) utilized clinically and commercially by Cyrex Laboratories, where he serves as chief scientific advisor and lead assay designer.

supports: Dysregulated Levels of Circulating Autoantibodies against Neuronal and Nervous System Auto… (Diagnostics (Basel, Switzerland) 2023) · cited 27x in the literature
"Levels of antibodies against the acetylcholine receptor, glutamate receptor, amyloid β peptide, alpha-synucleins, dopamine 1 receptor, dopamine 2 receptor, tau protein, GAD-65, N-methyl D-aspartate (NMDA) receptor, BDNF, cerebellar, ganglioside, myelin basic protein, myelin oligodendrocyte glycoprotein, S100-B, glial fibrillary acidic protein, and enteric nerve were measured using an Enzyme-Linked Immunosorbent Assay (ELISA)." (abstract, results, passage verified)
pubmed full study (doi)
supports: Immune Reactivity to Raw and Processed Foods and Their Possible Contributions to Autoimmun… (Foods (Basel, Switzerland) 2025) · cited 5x in the literature
"Immune reactions to undigested food antigens could result in the production of IgE antibodies, which are involved in immediate immune reactivity, and in IgG and IgA antibodies, which are involved in delayed immune reactivity. Currently, measurements of these antibodies are generally only performed against antigens derived from raw foods. However, testing for food reactivity based only on raw food consumption is inaccurate because people eat both raw and cooked foods." (abstract, results, passage verified)
pubmed full study (doi)

No source found (not proven false)

0:09:00 Dale Bredesenunverifiedvery low

Non-amnestic cortical presentations of Alzheimer's disease are more common in younger patients and in ApoE4-negative individuals.

"So these are what have often been called cortical presentations, which have been noted for years by people like Professor Mario Mendez to be typical in younger presentations of Alzheimer's and often in ApoE4-negative individuals." (said at 0:09:00)

No published record matching the claim that non-amnestic cortical presentations of Alzheimer's disease are more common in younger patients and in ApoE4-negative individuals was located; this does not prove the claim false.

0:15:12 Dale Bredesenunverifiedvery low

Approximately 7 million Americans are homozygous for the ApoE4 allele.

"Then about 7 million Americans have two copies, so they're homozygous for ApoE4." (said at 0:15:12)

No published record matching the claim that approximately 7 million Americans are homozygous for the ApoE4 allele was located; this does not prove the claim false.

0:28:56 Dale Bredesenunverifiedvery low

A businessman diagnosed with PET-scan-confirmed early Alzheimer's/MCI had mercury levels seven times the 95th percentile from heavy tuna sushi consumption and dental amalgams, and improved after reducing mercury exposure.

"one of the people who called me a couple years ago was a very successful businessman who had early Alzheimer's, had already had PET-scan proven... It turned out that he was eating large amounts of tuna sushi, and he happened to be genetically a poor excreter of mercury, also happened to have some dental amalgams... And his mercury was actually seven times the 95th percentile for our country—just one massive, massive mercury exposure. And he's done well with removing that." (said at 0:28:56)

No published record matching the claim of a patient with PET-scan-proven early Alzheimer's or mild cognitive impairment who had mercury levels seven times the 95th percentile from tuna sushi consumption and dental amalgams and subsequently improved after mercury reduction was located; this does not prove the claim false.

0:37:49 Dale Bredesenunverifiedvery low

Patients with MoCA scores of zero have shown cognitive improvement on Dr. Bredesen's protocol.

"Now, as you go later and later, it's more and more difficult, but we have seen people even with MoCA scores of zero show improvement." (said at 0:37:49)

No published record matching the claim that patients with baseline Montreal Cognitive Assessment (MoCA) scores of zero showed cognitive improvement on the Bredesen protocol was located; this does not prove the claim false. Published clinical studies evaluating the multimodal protocol have assessed individuals with subjective cognitive impairment, mild cognitive impairment, or early-stage dementia, with pilot trial inclusion criteria requiring baseline MoCA scores of 19 or higher.

The search did find related studies, but none that directly tests this claim:

context: Precision Medicine Approach to Alzheimer's Disease: Successful Pilot Project. (Journal of Alzheimer's disease : JAD 2022) · cited 70x in the literature
"Twenty-five patients with dementia or mild cognitive impairment, with Montreal Cognitive Assessment (MoCA) scores of 19 or higher, were evaluated for markers of inflammation, chronic infection, dysbiosis, insulin resistance, protein glycation, vascular disease, nocturnal hypoxemia, hormone insufficiency or dysregulation, nutrient deficiency, toxin or toxicant exposure, and other biochemical parameters associated with cognitive decline." (abstract, methods, passage verified)
pubmed full study (doi)

1:01:54 Dale Bredesenunverifiedvery low

In Alzheimer's subtype classification, purely toxic (type 3) represents 15 to 20 percent of cases, but 60 to 70 percent of patients show some degree of type 3 toxin or pathogen exposure.

"So although type 3, this toxin type, represented only about 15 or 20% of all of them that's pure, over 50%, typically in the 60 to 70% range, had at least some suggestion of the type 3. So in fact, most people have some sort of toxin exposure, pathogen exposure, that sort of thing." (said at 1:01:54)

Dr. Dale Bredesen proposed a metabolic and clinical classification scheme for Alzheimer's disease that includes Type 1 (inflammatory), Type 2 (atrophic), and Type 3 (cortical/toxic/inhalational, linked to biotoxins/mycotoxins). While published case series describe this proposed 'Type 3' toxic subtype, no peer-reviewed epidemiological studies or validated cohort datasets support the specific prevalence claims that purely toxic Alzheimer's represents 15-20% of cases or that 60-70% of Alzheimer's patients exhibit type 3 toxin/pathogen exposures. This classification system remains an unvalidated, non-standard framework in mainstream neurology based only on small case series.

The search did find related studies, but none that directly tests this claim:

context: Inhalational Alzheimer's disease: an unrecognized - and treatable - epidemic. (Aging 2016) · cited 46x in the literature
"Identifying subtypes of Alzheimer's disease may aid in the development of therapeutics, and recently three different subtypes have been described: type 1 (inflammatory), type 2 (non-inflammatory or atrophic), and type 3 (cortical). Here I report that type 3 Alzheimer's disease is the result of exposure to specific toxins, and is most commonly inhalational (IAD), a phenotypic manifestation of chronic inflammatory response syndrome (CIRS), due to biotoxins such as mycotoxins." (abstract, passage verified)
pubmed full study (doi)

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.